Hepatocyte growth factor activator inhibitor-1 (HAI-1) is a Kunitz-type transmembrane serine protease inhibitor that forms inhibitor complexes with several trypsin-like serine proteases and is required for mouse placental development and embryo survival. Here we show that the essential function of HAI-1 in placentation and all other embryonic processes is to restrict the activity of the type II transmembrane serine protease, matriptase. Enzymatic gene trapping of matriptase combined with HAI-1 immunohistochemistry revealed that matriptase is coexpressed with HAI-1 in both extraembryonic and embryonic tissues. As early as embryonic day 8.5, matriptase and HAI-1 were expressed in a population of chorionic trophoblasts. Ablation of HAI-1 disrupted the epithelial integrity of this cell population, causing disorganized laminin deposition and altered expression of E-cadherin and b-catenin. This led to a complete loss of undifferentiated chorionic trophoblasts after embryonic day 9.5 and prevented the formation of the placental labyrinth. Genetic ablation of matriptase activity in HAI-1-deficient embryos, however, restored the integrity of chorionic trophoblasts and enabled placental labyrinth formation and development to term. Furthermore, matriptase/HAI-1 double-deficient mice were phenotypically indistinguishable from matriptase single-deficient littermates.
Introduction
Cellular migration and differentiation during vertebrate morphogenesis have been hypothesized to depend on a finely tuned balance between extracellular proteases and their cognate inhibitors. Likely reflecting an extensive developmental redundancy, the genetic ablation of most extracellular protease inhibitors, however, either has no effect on organ formation (see Supplementary Material for references) or affects only the vascularization or homeostasis of formed organs (Gailani et al., 1997; Huang et al., 1997; Ishiguro et al., 2000; Oh et al., 2001; Zeeuwen et al., 2002; Ohmuraya et al., 2005) . Three notable exceptions to this are the serine protease inhibitors maspin, which is required for embryo implantation, and hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2, which are essential for, respectively, placental development and neural tube formation (Shimomura et al., 1997; Gao et al., 2004; Tanaka et al., 2005) .
HAI-1, the cognate inhibitor of hepatocyte growth factor activator, is a type I transmembrane protein that contains two extracellular Kunitz-type domains (Shimomura et al., 1997) . Kunitz-type domains are serine protease inhibitor domains that bind to the active site of trypsin-like serine proteases to form stable inhibitor complexes to restrict the proteolytic activity of their target proteases (Ascenzi et al., 2003) . Although originally isolated as an inhibitor of hepatocyte growth factor activator, HAI-1 also has been shown to display potent inhibitory activity towards the membrane-bound trypsin-like serine proteases, hepsin, prostasin, and matriptase (Lin et al., 1999; Fan et al., 2005; Herter et al., 2005) .
HAI-1-deficient mouse embryos display placental failure and mid-gestation resorption (Tanaka et al., 2005) , suggesting that the regulation of the activity of one or more extracellular proteases by HAI-1 could be essential for the development of this critical extraembryonic tissue. A proteolysis-independent role of HAI-1 in embryonic development has also been proposed (Tanaka et al., 2005) , because HAI-1 is an integral transmembrane protein with a cytoplasmic tail domain that is potentially capable of transducing extracellular signals, and because hepatocyte growth factor activator, hepsin, and matriptase are all dispensable for mouse embryonic development (Wu et al., 1998; List et al., 2002; Itoh et al., 2004) .
Matriptase is a type II transmembrane serine protease with a strictly epithelial pattern of expression in adult mouse and human tissues (Oberst et al., 2003a; List et al., 2006) . Gene targeting studies in mice have revealed an essential role of the protease in postnatal oral and epidermal barrier formation and hair follicle growth (List et al., 2002 (List et al., , 2006 . However, matriptasedeficient mice develop to term, and they display no obvious developmental abnormalities besides the skin and oral cavity.
We have recently shown that perturbing the balance between matriptase and HAI-1 in adult epidermis cause severe hyperplasia, abnormal cellular differentiation and malignant transformation (List et al., 2005) . Although matriptase is dispensable for embryonic development, this observation prompted us to examine if excess of matriptase proteolytic activity, nevertheless, could contribute to the developmental failure of HAI-1-deficient embryos. Interestingly, we found that inhibition of matriptase activity is the single non-redundant function of HAI-1 in placental development and other developmental processes. Thus, while loss of HAI-1 lead to the disruption of the epithelial integrity of a specific population of matriptase-expressing chorionic trophoblasts and their inability to form the placental labyrinth, matriptase/HAI-1 double-deficient mice displayed normal placentation, developed to term and displayed no phenotypic abnormalities besides those associated with the absence of matriptase.
Results
Matriptase is co-expressed with HAI-1 during placenta and embryo development To determine the expression of HAI-1 during embryonic development, we performed an immunohistochemical staining of staged mouse embryos (Figure 1 and Supplementary Figure 2) . Weak HAI-1 expression was detectable as early as embryonic day (E)8.5 in trophoblasts of the chorion (Figure 1a ). At E9.5 and E10.5, the expression of HAI-1 extended to include both chorionic trophoblasts and more differentiated trophoblasts in the labyrinth layer, identified as syncytiotrophoblasts based on their proximity to fetal vessels rather than maternal blood pools (Figure 1b-e) . At all stages investigated (E8.0-11.5), HAI-1 expression was also detected in the cuboidal endoderm of the visceral yolk sac (Figure 1f and data not shown). No expression was observed in the placental mesenchyme, in the fetal endothelial cells or in other sub-populations of trophoblasts, including spongiotrophoblasts and trophoblast giant cells (Figure 1a-c) .
To analyse the potential co-expression of matriptase with HAI-1 in these extraembryonic tissues, we took advantage of a recently generated knock-in mouse that expresses matriptase-b-galactosidase fusion protein from the endogenous matriptase promoter and can be used as a sensitive marker for matriptase expression using 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-gal) staining (List et al., 2006) . Weak matriptase expression was first detected in chorionic trophoblasts at E8.5 ( Figure 1g ) and was sustained in this population during the formation of the labyrinth layer at E9.5 and E10.5 (Figure 1h and i). Matriptase was not expressed in other trophoblast populations, in the yolk sac or in the placental mesenchyme ( Figure 1h and i and data not shown). When human placenta was examined at week 13 of gestation, HAI-1 (Figure 1k ) and matriptase ( Figure 1l ) were both expressed in villous trophoblasts that represent the epithelial lining of the human placental villous trees. The population of HAI-1-expressing cells in human placenta at week 13 or at term was identified as villous cytotrophoblasts, rather than terminally differentiated syncytiotrophoblasts, by the complementary pattern of expression with a syncytiotrophoblast marker human chorionic gonadotropin (Supplementary Figure 1) .
A tight co-expression of matriptase with HAI-1 extended also to the embryo proper. Both proteins were detected in the epithelial lining of several tissues, including the olfactory placode, the entrance to Rathke's pouch, the mandibular component of the first branchial arch, the pharyngeal region of the foregut, the midgut/hindgut region, the otic pit/otic vesicle and the periderm and germinal epithelium of the skin (Supplementary Figure 2 ).
HAI-1 ablation disrupts labyrinth layer morphogenesis
To further analyse the functional relationship between matriptase and HAI-1 during embryonic development, we next generated HAI-1-deficient mice by deleting the coding region of the HAI-1 gene (Figure 2a and b) , which lead to the loss of HAI-1 mRNA ( Figure 2c ) and HAI-1 protein in embryonic tissues (Figure 2d and data not shown). HAI-1-deficient embryos developed properly until E9.5, but thereafter displayed severe growth retardation (Figure 2e ). This lead to the resorption of all HAI-1-deficient embryos by E12.5, as revealed by genotype analysis of staged embryos from HAI-1 heterozygous breeding pairs ( Figure 2f ). As reported previously (Tanaka et al., 2005) , the placental labyrinth of HAI-1-deficient embryos was absent (Figure 2g and g 0 ), suggesting that the demise of embryos was due to the failure to establish the fetal-maternal interface required to sustain the rapid growth of the embryo that is taking place at this stage.
Placental labyrinth formation is initiated at E9.5 by the differentiation of chorionic trophoblasts and their migration towards the spongial layer. This is followed closely by the ingrowth of embryonic vessels that thereby are brought into close contact with maternal blood pools to form the placental labyrinth, as depicted schematically in Figure 3a (Kaufmann and Bart, 1999) . As syncytiotrophoblasts of the labyrinth and their chorionic precursors were the only cells that expressed HAI-1 (see above), we performed a detailed analysis of chorionic trophoblast population in HAI-1-deficient and -expressing placentas. Strikingly, the loss of HAI-1 resulted in the complete failure of chorionic trophoblasts to form the labyrinth layer ( Figure 3) . Thus, whereas chorionic trophoblasts in HAI-1-expressing embryos clearly displayed ingrowth towards the spongial layer at E9.5 (Figure 3b ), no such process was observed in the HAI-1-deficient placentas (Figure 3b 0 ). Furthermore, in HAI-1-expressing placentas, the chorionic trophoblasts were detectable as a keratin-and p57/Kip2-negative (marker for terminally differentiated trophoblasts; Riley et al., 1998) sheath of cells in contact with the fetal mesenchyme during the labyrinth formation (Figure 3c .5, weak matriptase expression (cyan staining, arrows) is restricted to the chorionic trophoblasts. The selective expression of matriptase in chorionic trophoblasts (arrows in (h) and (i)), but not in differentiated trophoblasts of the labyrinth, spongiotrophoblasts, trophoblast giant cells or emerging fetal vessels (arrowheads) at E9.5 (h) and E10.5 (i). High magnification (j) of a section double-stained with HAI-1 (brown) and X-gal (cyan) showing colocalization of matriptase and HAI-1 in chorionic trophoblasts (arrows). Expression of HAI-1 (k) and matriptase (l) in villous cytotrophoblasts of week 13 human placenta (arrows), but not in villous mesenchyme ('M' in (k) and (l)). A layer of HAI-1-negative syncytiotrophoblasts is indicated by arrowheads in (k). Sections in (a)-(f) and (j)-(l) were counterstained with hematoxylin, and sections in (g)-(i) with nuclear fast red. Size bars: a and g, 50 mm; b, c, h and i, 100 mm; d-f, 15 mm; and j-l 25 mm.
Membrane protease inhibition in embryonic development R Szabo et al spongiotrophoblasts, or in other parts of the developing placenta, as assessed by H&E staining for necrosis or abnormal tissue architecture, TdT-mediated dUTP nick end labelling assays for apoptosis, Ki67 staining for proliferation or p57/Kip2 staining ( Figure 3b 0 -e 0 and data not shown).
Interestingly, in situ hybridization for spongiotrophoblast marker Tpbp showed that the space between the allantoic mesenchyme and the spongial layer in these placentas is filled with a population of non-spongiotrophoblast cells (Supplementary Figure 4) , suggesting that loss of HAI-1 does not ablate chorionic trophoblast Membrane protease inhibition in embryonic development R Szabo et al population, but rather perturbs the differentiation program of these cells.
HAI-1 ablation disrupts the integrity of chorionic trophoblasts prior to the initiation of labyrinth formation Because chorionic trophoblasts expressed both HAI-1 and matriptase already at E8.5 (see above), we investigated if the failure of placental development was caused by the perturbance of this cell population prior to the initiation of labyrinth formation at E9.5. Whereas chorionic trophoblasts of HAI-1-deficient placentas appeared normal at E8.5 when compared to HAI-1-expressing chorionic trophoblasts (Figure 4a and 4a 0 ), already at E9.0, this cell population was grossly abnormal in HAI-1-deficient placentas. Thus, whereas chorionic trophoblasts of HAI-1-expressing placentas presented as a distinct epithelial sheath of cells that deposited a well-organized, laminin-containing membrane (Figure 4b and c) , this cell layer was completely disrupted in HAI-1-deficient placentas and displayed Membrane protease inhibition in embryonic development R Szabo et al disorganized laminin deposition (Figure 4b 0 ). As a consequence, no laminin membrane was observed at E9.5 (Figure 4c 0 ). Owing to their expression of matriptase, the aberrantly developing chorionic trophoblasts in HAI-1-deficient placentas could still be identified at E9.5, where they appeared as scattered clusters of matriptase-positive cells or as single matriptase-positive cells (compare Figure 4d 0 with d). Moreover, E-cadherin displayed an abnormal punctate appearance in this cell population (compare Figure 4e 0 and e), and b-catenin immunostaining was either strongly reduced or largely absent from the periphery of the cell membrane (compare Figure 4f 0 and f 00 with Figure 4f ). In accordance with this, Western blot analysis of protein lysates from HAI-1-deficient placentas at E9.5 showed reduced levels of both E-cadherin (Figure 4g , top panel) and b-catenin (Figure 4g , bottom panel), reflecting a quantitative loss of chorionic trophoblast precursor cells and/or the aberrant expression of the two epithelial markers by these cells. Taken together, these results suggest that excess matriptase activity in HAI-1-deficient placentas caused a disruption of the epithelial integrity of a population of matriptaseexpressing chorionic trophoblasts, leading to the perturbance of their normal differentiation and subsequent failure to form the placental labyrinth.
Combined loss of both matriptase and HAI-1 results in normal placentation and term development Based on the above findings, we hypothesized that the functional defects in HAI-1-deficient chorionic trophoblasts could be alleviated by the simultaneous removal of matriptase, and that matriptase/HAI-1 doubledeficient embryos, therefore, would be capable of placental labyrinth formation. To challenge this hypothesis, we crossed HAI-1-heterozygous mice to previously generated mice carrying a matriptase allele disrupted either by conventional gene targeting (List et al., 2002) or by insertion of the b-galactosidase marker gene (List et al., 2006) . The resulting matriptase/HAI-1 doubleheterozygous mice were then interbred, and their offspring was genotyped at birth. As expected from the above experiments, out of 130 matriptase-expressing pups (matriptase þ / þ or matriptase þ /À) born from matriptase/HAI-1 double-heterozygous breeding pairs, 45 were wild type and 85 were heterozygous for the targeted HAI-1 allele, while no HAI-1-negative pups were detected (Figure 5a) . Strikingly, however, among the matriptase-deficient offspring born from these crosses, the distribution of the HAI-1 wild type, heterozygous and null alleles in newborn pups displayed a normal Mendelian distribution (Figure 5a and b) . Thus, of 57 matriptase-deficient pups, 15 were wild type, 29 were heterozygous and 13 were homozygous for the targeted HAI-1 allele (Po0.001 relative to matriptaseexpressing pups, w 2 analysis, two-tailed). As expected, immunostaining of the skin (Figure 5d 00 ) and other organs (data not shown) of newborn matriptase/HAI-1 double-deficient mice showed the complete absence of HAI-1 immunoreactivity. Macroscopic examination of newborn matriptase/HAI-1 double-deficient pups did not reveal any obvious abnormalities besides the epidermal defects associated with loss of matriptase, including abnormally thin, reddish, wrinkled and dry epidermis (Figure 5c ), and the absence of erupted whiskers (data not shown). All matriptase singledeficient and matriptase/HAI-1 double-deficient pups died within the first day after birth with no obvious difference in survival time. Also, milk spots were missing from the stomachs of about 75% of the matriptase single-deficient and matriptase/HAI-1 double-deficient pups (examples in Figure 5c ). Histological analysis of the skin of newborn matriptase/HAI-1 double-deficient pups revealed an abnormal structure of the stratum corneum with tightly packed layers of immature corneocytes (compare Figure 5d and d 00 ), identical to the skin of matriptase single-deficient littermate mice (Figure 5d 0 ). Also, similar to matriptase single-deficient pups, histological examination of a number of other organs and tissues of matriptase/HAI-1 double-deficient pups did not reveal any overt abnormalities (data not shown).
We next analysed the development of HAI-deficient placentas in the absence of matriptase. Notably, the failure of HAI-1-deficient chorionic trophoblasts to migrate towards the spongial layer was completely restored by the added deficiency of matriptase. This led to normal labyrinth layer formation (Figure 5e -e 00 ) and reversion of the growth retardation of the embryo proper (data not shown). Moreover, the chorionic trophoblasts presented normally in matriptase/HAI-1 double-deficient placentas (Figure 5f and g) despite the loss of HAI-1 expression (compare Figure 5f and h). Taken together, these data show that loss of both the membrane protease and its inhibitor are compatible with development, whereas single deficiency in HAI-1 disrupts embryonic development as a consequence of excessive matriptase activity.
Discussion
The type II transmembrane serine protease matriptase is essential for postnatal survival, but dispensable for development to term. In this paper, we reached the unexpected conclusion that matriptase activity, nevertheless, needs to be tightly regulated for embryonic development to occur, and that the Kunitz-type transmembrane serine protease inhibitor HAI-1 is one essential matriptase inhibitor. This conclusion was based on the following observations: (a) Matriptase displayed colocalization with HAI-1 during the development of both extraembryonic and embryonic tissues. (b) Loss of HAI-1 specifically disrupted the integrity of a population of matriptase-expressing chorionic trophoblasts, preventing the formation of the placental labyrinth. (c) HAI-1-deficient mice displayed normal placentation and development to term when placed on a matriptase-deficient background. The co-expression of matriptase and HAI-1 in the developing placenta was observed not only in mice but also in humans, indicating that inhibition of matriptase by HAI-1 may be required also for placental development in other mammals, and perturbation of the matriptase-HAI-1 balance could merit investigation as a cause of early miscarriage.
It is important to emphasize that our data do not show that matriptase necessarily is the only target for HAI-1 during development. Thus, our data are not incompatible with HAI-1 having several other important protease targets during development, but the inhibition of these proteases by HAI-1 then must be redundant with other inhibitors. Besides matriptase, HAI-1 has been reported to form inhibitor complexes with the serine proteases hepatocyte growth factor ) in the upper layers of the epidermis and hair follicles, and an abnormally compact stratum corneum similar to that of matriptase-deficient skin (arrowheads in (d 0 ) and (d 00 )). (e and e 00 ) Micrographs of H&E staining of the placental tissue of wild type (e), HAI-1-deficient (e 0 ) and matriptase/HAI-1 double-deficient (e 00 ) placentas at E10.5 showing restoration of labyrinth layer formation in matriptase/HAI-1 double-deficient placentas. HAI-1-expressing and matriptase/HAI-1 double-deficient placentas both display fetal vessels (arrowheads in (e) and (e 00 )) in the labyrinth layer. In sharp contrast, no chorionic trophoblasts are present in the HAI-1 single-deficient placentas (e 0 ). (f-h) Combined X-gal and HAI-1 immunostaining (f), X-gal and keratin immunostaining (g) and HAI-1 immunostaining (h) of matriptase/HAI-1 double-deficient (f and g) and matriptase and HAI-1-expressing placentas (h) showing the presence and normal appearance of HAI-1-negative (compare brown staining in (f) and (h)), keratin-negative (brown staining in (g)) chorionic trophoblasts (arrows in (f) and (g)) in matriptase/HAI-1 double-deficient placentas that transcribe the matriptase alleles (cyan staining, arrows in (f) and (g)). Sections in (d) and (d 00 ) and (f)-(h) were counterstained with hematoxylin. Size bars: d, d
0 , d 00 , 25 mm; e, e 0 , e 00 , 75 mm; f-h, 25 mm.
activator, hepsin and prostasin, and may have additional unidentified targets (see Introduction). It is therefore formally possible that HAI-1 does not act directly on matriptase during development, but rather on other proteases that act either upstream or downstream of matriptase in a matriptase-dependent proteolytic pathway. However, for the following reasons this does not seem likely: First, biochemical studies have shown that HAI-1 binds directly to matriptase with high affinity and efficiently inhibits matriptase proteolytic activity (Oberst et al., 2003b (Oberst et al., , 2005 . Second, shed endogenous matriptase has been isolated in a complex with shed endogenous HAI-1 in breast milk, indicating that a direct interaction occurs between matriptase and HAI-1 when co-expressed in vivo (Lin et al., 1999) . Third and most importantly, we found no evidence of expression of mRNA for hepatocyte growth factor activator in mouse placentas by reverse transcriptionpolymerase chain reaction (PCR), and prostasin and matriptase were expressed in different populations of cells in the developing placenta (R Szabo and TH Bugge, unpublished data). Why would matriptase and HAI-1 be expressed during placental development if the combined deficiency in both is compatible with normal placentation, and excessive expression of the protease could place the embryo at risk for developmental failure? Three scenarios appear equally possible: The regulatory elements that confer matriptase expression in the developing embryo may be identical to those required to confer expression of the protease in tissues where it is needed (e.g. epidermis and oral epithelium) and the embryonic matriptase expression will be evolutionarily conserved despite providing no benefit. Alternatively, matriptase has a critical function in development, but this function is redundant with closely related proteases such as matriptase-2 (Velasco et al., 2002; Hooper et al., 2003) and matriptase-3 . Finally, embryonic matriptase expression may be important for development only under environmental stress conditions (infection, intoxication, malnutrition, heat/cold exposure, other) that do not present under standard animal housing conditions.
Matriptase and HAI-1 also are co-expressed in a large number of tissues of the embryo proper, including the developing oropharynx, olfactory system, intestine and skin (this study), as well as in a number of adult tissues in mice (K List and T Bugge, unpublished data) and humans (Oberst et al., 2003a) . It therefore seems likely that HAI-1 also may have an essential role in restricting matriptase activity in these tissues, and that even if placentation could be restored, HAI-1 deficiency would not be compatible with term development or adult life.
Multiple molecular mechanisms by which excessive matriptase activity in HAI-1-deficient chorionic trophoblast precursors may lead to the disruption of epithelial integrity, aberrant differentiation and subsequent failure of these cells to produce a progeny of labyrinth-forming cells are possible. The premature activation of matriptase in the secretory pathway caused by HAI-1 deficiency may be toxic to the chorionic trophoblast precursor cells, triggering their demise or aberrant differentiation. Alternatively, excess cell surface matriptase activity may lead to cleavage of substrates that are not normally cleaved by matriptase, such as components of the emerging basement membrane that is being organized by chorionic trophoblasts at this developmental stage or components of their cell-cell junctions. Equally plausible, loss of HAI-1 may lead to pathologically increased cleavage of substrate(s) that are normally cleaved by matriptase. The epithelial sheath of chorionic trophoblasts that express matriptase prior to labyrinth formation is quite small (roughly 0.5 mm 2 ). A direct biochemical/proteomic analysis of this tissue from HAI-1-expressing and HAI-1-deficient embryos to identify matriptase proteolytic targets therefore may prove challenging. A systematic screening for the expression of known candidate matriptase substrates in these cells, followed by a genetic analysis to test if the specific ablation of each of these candidate substrates can rescue placental formation in HAI-1-deficient embryos, appear likely to be more productive.
Taken together, our studies have identified matriptase as the single non-redundant target for HAI-1 during mouse embryonic development and have provided the mechanistic basis for the failure of HAI-1-deficient mice to form a functional placenta.
Materials and methods

Gene targeted mice
The generation of conventional matriptase knockout and b-galactosidase-tagged matriptase knock-in mice has been described (List et al., 2002 (List et al., , 2006 . To generate HAI-1 knockout mice, a 4.8 kb fragment of the 5 0 -untranslated region (long arm) and a 2.5 kb fragment of the 3 0 -untranslated region (short arm) of the mouse HAI-1 gene were amplified from mouse 129/SvEvTac genomic DNA by long-range PCR, using the Expand Long DNA Template kit (Roche, Indianapolis, IN, USA) according to the manufacturer's instructions. The primers used for the amplification were L51 (5 0 -CTAGCTC GAGTGTGTTCTCACCACTGAACC-3 0 ) and L31 (5 0 -TCA GCTCGAGTGAACACCAGAAGTGCGTCCC-3 0 ) for the long arm, and S52 (5 0 -TAGACCGCGGCATATCTCTA CCTTCCTGTCC-3 0 ) and S32 (5 0 -TGACGCGGCCGCATT CTGTAGAGTAGGCTTGCC-3 0 ) for the short arm. The HAI-1 targeting vector was generated by cloning the long arm DNA into the XhoI restriction site of the pKO1907 Scrambler vector (Stratagene, La Jolla, CA, USA) followed by the cloning of the short arm into the NotI/SacII sites of the same vector. The targeting vector was linearized with PvuI, transfected into the 129/SvEvTac embryonic stem (ES) cells by electroporation, and the positive clones were identified by Southern blot hybridization of DrdI-digested genomic DNA using a 32 P-labeled DNA probe corresponding to the 3 0 -untranslated region of the HAI-1 gene, which was external to the targeting vector sequence. The HAI-1-targeted ES cells were injected into the blastocoel cavity of C57Bl/6J-derived blastocysts and implanted into pseudopregnant females. The resulting chimeric male offspring was bred to NIH Black Swiss females (Taconic Farms, Germantown, NY, USA) to generate offspring carrying one HAI-1-targeted allele. Genotyping of animals from ear and yolk sac biopsies was performed by PCR with primers HAI-54 (5 0 -CTGTCTGTTTACCTTGTCTCG-3 0 )
and HAI-34 (5 0 -TAAAGGGATGTTGTCCTGGG-3 0 ) for the wild-type allele and HAI-KOR51 (5 0 -GAGAATTCCTA GAGGTACCC-3 0 ) and HAI-KOR31 (5 0 -GGTAGTTGAGG GAACATGGC-3 0 ) for the HAI-1-targeted allele.
Extraction of embryonic and perinatal tissues Breeding females were checked for vaginal plugs in the morning and the day on which the plug was found was defined as the first day of pregnancy (E0.5). The pregnant females were euthanized in the mid-day at designated time points by CO 2 asphyxiation. Embryos were extracted by Caesarian section and the individual embryos and placentas were dissected and processed as described below. Visceral yolk sacs of individual embryos were washed twice in phosphatebuffered saline (PBS), subjected to genomic DNA extraction and genotyped by PCR. Paraffin sections of 13th week human placenta were purchased from BioChain (Hayward, CA, USA). Newborn pups were euthanized by CO 2 inhalation at 01C. Skins or whole pups were fixed for 24 h in 4% paraformaldehyde (PFA) in PBS, processed into paraffin, sectioned into parallel sagittal sections and stained with H&E, or used for immunohistochemistry as described below.
Whole-mount histological analysis and b-galactosidase staining Tissue samples were fixed for 30 min in 4% PFA in PBS, rinsed in PBS and stained with a b-galactosidase staining kit (Roche) for 6 h at 371C using X-gal as the substrate. The tissues were post-fixed overnight in 4% PFA, embedded in paraffin and sectioned.
Immunohistochemistry
Tissues were fixed overnight in 4% PFA, embedded in paraffin and cut into 5-mm-thick sections. Antigens were retrieved by incubation for 10 min at 371C with 10 mg/ml proteinase K (Fermentas, Hanover, MD, USA) for HAI-1 staining, or by incubation for 20 min at 1001C in 0.01 M sodium citrate buffer, pH 6.0, for all other antigens. The sections were blocked with 2% bovine serum albumin in PBS, and incubated overnight at 41C with the primary antibody (see Supplementary Methods). Bound antibodies were visualized using biotin-conjugated antimouse, -rabbit, rat or -goat secondary antibodies (Vector Laboratories, Burlingame, CA, USA) and a Vectastain ABC kit (Vector Laboratories) using 3,3 0 -diaminobenzidine as the substrate (Sigma Chemical Co, St Louis, MO, USA). All microscopic images were acquired on Olympus BX40 microscope using Olympus DP70 digital camera system (both Olympus, Melville, NY, USA).
Western blotting
The fetal part of E9.5 placentas was separated from the decidua by manual microdissection. The proteins were extracted by homogenizing the microdissected tissue in lysis buffer (62.5 mM Tris/HCl, pH 6.8, 2% SDS, 10% glycerol) and subjected to a Western blot analysis as described previously using primary anti-E-cadherin (InvitrogenZymed, San Francisco, CA, USA) or anti-b-catenin (Sigma) antibodies.
Abbreviations E, embryonic day; ES, embryonic stem (cells); HAI, hepatocyte growth factor activator inhibitor; X-gal, 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside.
